Scoop: A Soft­Bank-backed biotech rais­es more funds af­ter bag­ging $100M+ for fun­gi min­ing

A biotech min­ing fun­gi to find new drugs for can­cer and in­fec­tious dis­eases is rais­ing an­oth­er round of fi­nanc­ing, End­points News has learned.

Hexa­gon Bio has so far raised $67 mil­lion in a new round, the com­pa­ny con­firmed to End­points. An SEC fil­ing de­tails the to­tal of­fer­ing could even­tu­al­ly go be­yond that fig­ure, to al­most $80 mil­lion. The first sale in the Men­lo Park, CA, biotech’s of­fer­ing was Sept. 30.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER